PreventIon of CArdiovascular Events in iSchemic Stroke Patients With High Risk of Cerebral HemOrrhage
- Conditions
- Brain IschemiaIntracranial Hemorrhages
- Interventions
- Device: ankle-brachial index (ABI)Device: intima-medial thickness (IMT)Device: new asymptomatic brain hemorrhageDevice: new ischemic lesions on follow-up FLAIR images
- Registration Number
- NCT01013532
- Lead Sponsor
- Asan Medical Center
- Brief Summary
Through this study, the investigators are to prove that Cilostazol effectively prevent cardiovascular events in ischemic stroke patients with high risk of cerebral hemorrhage, along with no significant increase in the risk of occurrence of hemorrhagic side effects.
The primary hypothesis of this study is; Cilostazol alone or with probucol will reduce the risk of cerebral hemorrhage without increase of cardiovascular events compared to aspirin in the ischemic stroke patients with symptomatic or asymptomatic old cerebral hemorrhage.
This study will prove the superiority of cilostazol on the prevention of cerebral hemorrhagic events without increasing the cardiovascular events against aspirin and the superiority of probucol on the prevention of overall cardiovascular events.
- Detailed Description
It has been generally accepted that 'old age' and 'hypertension' may be risk factors not only for cerebral infarction but also for cerebral hemorrhage. Usually 40 to 60 percent of recurrent strokes after cerebral hemorrhage cases are cerebral infarction; and 5 to 10 percent of recurrent stroke after cerebral infarction cases are cerebral hemorrhage.
Consequently, for the reasons described above, hemorrhagic side effects including cerebral hemorrhage have been a great concern, in the usage of antiplatelet agent or anticoagulant for the secondary prevention in the patients with cerebral infarction.
It is reported that the occurrence of cerebral hemorrhage tends to increase in cases of accompanying lacunar infarction which occurs more frequently in Asians than in Westerners, or periventricular ischemic change which increasingly occurs with ageing. Accordingly, the point is that the occurrence of cerebral hemorrhage should be primarily considered in the treatment of cerebral infarction, along with the phenomenon of an ageing population both in Asian countries including Korea.
Nevertheless, so far there has been no clinical research regarding secondary prevention of stroke, particularly considering the risk of occurrence of hemorrhage in cerebral infarction cases. However, according to a recent study, when phosphodiesterase inhibitors including Cilostazol are used independently, or in combination with aspirin, secondary prevention can be improved without increasing the occurrence of hemorrhagic side effects.
Considering this, if it is proved that the agent, Cilostazol, could decrease the risk of occurrence of stoke, along with no significant increase in the risk of occurrence of hemorrhagic side effects, by selecting a patent group with a high risk of cerebral hemorrhage, the agent (Cilostazol) may be recognized as an unique antiplatelet agent applicable to old-aged patient with cerebral infarction who have a certain risk of cerebral hemorrhage.
* High risk of cerebral hemorrhage is defined as presence of history of cerebral hemorrhage with appropriate neuroimage findings or presence of asymptomatic old cerebral hemorrhage findings(equal or more than 8mm) or multiple microbleeds on the GRE images.
* 1600 ischemic stroke patients with high risk of cerebral hemorrhage will be recruited and they are randomized into four groups (cilostazol plus probucol, aspirin plus probucol, cilostazol and aspirin) by 2X2 factorial design.
* IMT and ABI will be measured every year during follow-up period and the results will be compared with the baseline data. The change of IMT and ABI will be analyzed with the occurrence of cardiovascular events.
* The study will finish at least 1 year after the recruit of 1600th patients. Until the finish, all patients will continuously take study medications and visit every 3months at the study site.
* Brain MRI including FLAIR and GRE will be done at the final visits.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 1600
- Patients with transient ischemic attack (TIA) or ischemic stroke within 180 days prior to screening - Adult aged 20 years or older
- High risk of hemorrhagic stroke (history of intracranial hemorrhage or imaging evidence of previous intracranial hemorrhage)
- Informed consent
- Clinical diagnosis of myocardial infarction or coronary intervention within 4 weeks
- Bleeding tendency
- Pregnant or breast-feeding woman
- Hemorrhagic stroke within 6 months
- Patient who was taking antithrombotic medication other than aspirin and does not agree to change the previous medication
- Severe cardiovascular disease such as cardiomyopathy or congestive heart failure
- Life expectancy less than one year
- Contraindication to long term aspirin use
- Enrolled in other clinical trial within 30 days
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- FACTORIAL
- Arm && Interventions
Group Intervention Description Cilostazol+ Probucol Cilostazol 100mg cilostazol bid plus probucol plus placebo of aspirin Cilostazol+ Probucol Probucol 100mg cilostazol bid plus probucol plus placebo of aspirin Cilostazol+ Probucol placebo of aspirin 100mg cilostazol bid plus probucol plus placebo of aspirin Cilostazol+ Probucol ankle-brachial index (ABI) 100mg cilostazol bid plus probucol plus placebo of aspirin Cilostazol+ Probucol intima-medial thickness (IMT) 100mg cilostazol bid plus probucol plus placebo of aspirin Cilostazol+ Probucol new asymptomatic brain hemorrhage 100mg cilostazol bid plus probucol plus placebo of aspirin Cilostazol+ Probucol new ischemic lesions on follow-up FLAIR images 100mg cilostazol bid plus probucol plus placebo of aspirin Aspirin + Probucol placebo of cilostazol aspirin plus placebo cilostazol plus probucol Aspirin + Probucol intima-medial thickness (IMT) aspirin plus placebo cilostazol plus probucol Aspirin + Probucol ankle-brachial index (ABI) aspirin plus placebo cilostazol plus probucol Aspirin + Probucol new asymptomatic brain hemorrhage aspirin plus placebo cilostazol plus probucol Aspirin + Probucol new ischemic lesions on follow-up FLAIR images aspirin plus placebo cilostazol plus probucol Cilostazol placebo of aspirin cilostazol plus placebo of aspirin Cilostazol ankle-brachial index (ABI) cilostazol plus placebo of aspirin Cilostazol intima-medial thickness (IMT) cilostazol plus placebo of aspirin Cilostazol new asymptomatic brain hemorrhage cilostazol plus placebo of aspirin Cilostazol new ischemic lesions on follow-up FLAIR images cilostazol plus placebo of aspirin Aspirin placebo of cilostazol aspirin plus placebo of cilostazol Aspirin ankle-brachial index (ABI) aspirin plus placebo of cilostazol Aspirin intima-medial thickness (IMT) aspirin plus placebo of cilostazol Aspirin new asymptomatic brain hemorrhage aspirin plus placebo of cilostazol Aspirin new ischemic lesions on follow-up FLAIR images aspirin plus placebo of cilostazol Aspirin + Probucol Probucol aspirin plus placebo cilostazol plus probucol Aspirin + Probucol Aspirin aspirin plus placebo cilostazol plus probucol Cilostazol Cilostazol cilostazol plus placebo of aspirin Aspirin Aspirin aspirin plus placebo of cilostazol
- Primary Outcome Measures
Name Time Method Time to the first occurrence of cerebral hemorrhage time since randomization; follow-up period is 1.0 to 5.5 years Time to the first occurence of composite cardiovascular events time since randomization; follow-up period is 1.0 to 5.5 years
- Secondary Outcome Measures
Name Time Method Time to the first occurrence of stroke time since randomization; follow-up period is 1.0 to 5.5 years Time to the first occurrence of ischemic stroke time since randomization; follow-up period is 1.0 to 5.5 years Time to the first occurence of myocardial infarction time since randomization; follow-up period is 1.0 to 5.5 years Time to the first occurence of other designated vascular events time since randomization; follow-up period is 1.0 to 5.5 years
Trial Locations
- Locations (71)
Pamela Youde Nethersole Eastern Hospital
🇨🇳Hong Kong, Hong Kong, China
Queen Elizabeth Hospital
🇨🇳Hong Kong, Hong Kong, China
United Christian Hospital
🇨🇳Hong Kong, Hong Kong, China
Prince of Wales Hospital
🇨🇳Shatin, NT, Hong Kong, China
Chungbuk National University Hospital
🇰🇷Cheongju, Chungbuk, Korea, Republic of
Soonchunhyang University Cheonan Hospital
🇰🇷Cheonan, Chungcheongnam-do, Korea, Republic of
Wonju Christian Hospital
🇰🇷Wonju, Gangwon-do, Korea, Republic of
Kwandong University College of Medicine Myongji Hospital
🇰🇷Gyeonggi-do, Goyang, Korea, Republic of
Gyeongsang National University Hospital
🇰🇷Jinju, Gyengsangnam-do, Korea, Republic of
Korea University Ansan Hospital
🇰🇷Ansan, Gyeonggi-do, Korea, Republic of
Scroll for more (61 remaining)Pamela Youde Nethersole Eastern Hospital🇨🇳Hong Kong, Hong Kong, China